Banner Image for CVR Staff

Duke-NUS - Pre-hospital & Emergency Research Centre

Crowston Jonathan Guy

Adjunct Professor

Senior Consultant Glaucoma,  Singapore National Eye Centre


Contact: 66014127

Dr Crowston is a Professor of Ophthalmology in the Neuroscience and Behavioural Disorders programme at Duke-NUS Medical School, and a glaucoma consultant at the Singapore National Eye Centre. His research focuses on understanding why ageing predisposes individuals to optic nerve damage in glaucoma, and developing new therapeutic approaches to boost neuronal repair.

He obtained his medical degree at the Royal Free Hospital SOM, London, and a PhD at University College London. Following ophthalmology training at Moorfields Eye Hospital, he completed glaucoma fellowships at Westmead Hospital in Sydney and the University of California, San Diego. He was subsequently appointed as a faculty member in the University of California, San Diego, and served as Director of the Hamilton Glaucoma Center Basic Research Laboratories. He moved to Melbourne in July 2006 and established the Glaucoma Research Laboratory at the Centre for Eye Research Australia (CERA). He was subsequently appointed as Head of Ophthalmology at the University of Melbourne and Director of CERA.

The goal of our research is to understand why advancing age predisposes to loss of retinal ganglion cells and from this determine new therapeutic approaches for protecting the optic nerve in glaucoma and other optic neuropathies.

We have discovered that retinal ganglion cells in mice enter a “comatose” non-functional state after injury but retain the capacity for functional recovery. Age is a major determinant of how well retinal ganglion cells recover following an acute intraocular pressure challenge. Importantly, this negative effect of aging is modifiable. Diet restriction and exercise profoundly improving the rate of functional recovery and synapse reformation. A specific focus is the role of bioenergetic compromise on retinal ganglion cell vulnerability.  Together with Ian Trounce in Melbourne we have demonstrated impaired mitochondrial activity in glaucoma patients, specifically in complex-I of the electron transport chain (OXPHOS). We are now aiming to uncover the key pathways involved in driving neurorecovery.

Another key area of our research is to develop diagnostic tests that inform on the state of RGC health. We believe these are needed to facilitate translation of candidate neuroprotective treatments into clinical trial. Functional recovery is increasingly recognised in response to treatment in human glaucoma. We have recently completed a clinical trial demonstrating visual recovery in human glaucoma in response to nicotinamide, a larger clinical study is in train.

  1. Wong CW, Foo LL, Morjaria P, Morgan I, Mueller A, Davis A, et al. Highlights from the 2019 International Myopia Summit on 'controversies in myopia'. Br J Ophthalmol. 2020.
  2. Tang J, Hui F, Hadoux X, Soares B, Jamieson M, van Wijngaarden P, et al. Short-Term Changes in the Photopic Negative Response Following Intraocular Pressure Lowering in Glaucoma. Invest Ophthalmol Vis Sci. 2020;61(10):16.
  3. Shah MH, Chan EC, Van Bergen NJ, Pandav SS, Ng S, Crowston JG, et al. Nox4 Facilitates TGFbeta1-Induced Fibrotic Response in Human Tenon's Fibroblasts and Promotes Wound Collagen Accumulation in Murine Model of Glaucoma Filtration Surgery. Antioxidants (Basel). 2020;9(11).
  4. Mursch-Edlmayr AS, Ng WS, Diniz-Filho A, Sousa DC, Arnold L, Schlenker MB, et al. Artificial Intelligence Algorithms to Diagnose Glaucoma and Detect Glaucoma Progression: Translation to Clinical Practice. Transl Vis Sci Technol. 2020;9(2):55.
  5. Lopez Sanchez MIG, Ziemann M, Bachem A, Makam R, Crowston JG, Pinkert CA, et al. Nuclear response to divergent mitochondrial DNA genotypes modulates the interferon immune response. PLoS One. 2020;15(10):e0239804.
  6. Kezic JM, Chrysostomou V, McMenamin PG, Crowston JG. Effects of age on retinal macrophage responses to acute elevation of intraocular pressure. Exp Eye Res. 2020;193:107995.
  7. Kadziauskiene A, Chua J, Baskaran M, Yow AP, Tan B, Sng C, et al. Association Between Structure-function Characteristics and Visual Field Outcomes in Glaucoma Subjects With Intraocular Pressure Reduction After Trabeculectomy. J Glaucoma. 2020;29(8):648-55.
  8. Hui F, Tang J, Williams PA, McGuinness MB, Hadoux X, Casson RJ, et al. Improvement in inner retinal function in glaucoma with nicotinamide (vitamin B3) supplementation: A crossover randomized clinical trial. Clin Exp Ophthalmol. 2020;48(7):903-14.
  9. Foreman J, Keel S, McGuinness MB, Crowston JG, Taylor HR, Dirani M. Prevalence and associations of non-retinopathy ocular conditions among older Australians with self-reported diabetes: The National Eye Health Survey. Int J Ophthalmol. 2020;13(10):1642-51.
  10. Foreman J, Crowston JG, Dirani M. Is physical activity protective against myopia? Br J Ophthalmol. 2020;104(10):1329-30.
  11. Chua J, Kadziauskiene A, Wong D, Asoklis R, Lesinskas E, Quang ND, et al. One year structural and functional glaucoma progression after trabeculectomy. Sci Rep. 2020;10(1):2808.
  12. Chong RS, Crowston JG, Wong TT. Experimental models of glaucoma filtration surgery. Acta Ophthalmol. 2020.
  13. Chong RS, Busoy JMF, Tan B, Yeo SW, Lee YS, Barathi AV, et al. A Minimally Invasive Experimental Model of Acute Ocular Hypertension with Acute Angle Closure Characteristics. Transl Vis Sci Technol. 2020;9(7):24.
  14. Casson RJ, Chidlow G, Crowston JG, Williams PA, Wood JPM. Retinal energy metabolism in health and glaucoma. Prog Retin Eye Res. 2020:100881.
  15. Ang GS, Fenwick EK, Constantinou M, Gan ATL, Man REK, Casson RJ, et al. Selective laser trabeculoplasty versus topical medication as initial glaucoma treatment: the glaucoma initial treatment study randomised clinical trial. Br J Ophthalmol. 2020;104(6):813-21.
  16. Yan MK, Kumar H, Kerr N, Medeiros FA, Sandhu SS, Crowston J, et al. Transnational review of visual standards for driving: How Australia compares with the rest of the world. Clin Exp Ophthalmol. 2019;47(7):847-63.
  17. Wu Z, Crabb DP, Chauhan BC, Crowston JG, Medeiros FA. Improving the Feasibility of Glaucoma Clinical Trials Using Trend-Based Visual Field Progression Endpoints. Ophthalmol Glaucoma. 2019;2(2):72-7.
  18. Kwon HJ, Kumar H, Green CM, Crowston JG, McGuinness MB, Kerr NM. Bleb-associated endophthalmitis: Proportion, presentation, management and outcomes in Victoria, Australia. Clin Exp Ophthalmol. 2019;47(5):588-97.
  19. Keel S, Xie J, Foreman J, Lee PY, Alwan M, Fahy ET, et al. Prevalence of glaucoma in the Australian National Eye Health Survey. Br J Ophthalmol. 2019;103(2):191-5.
  20. Hadoux X, Hui F, Lim JKH, Masters CL, Pebay A, Chevalier S, et al. Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease. Nat Commun. 2019;10(1):4227.
  21. Dirani M, Crowston JG, Wong TY. From reading books to increased smart device screen time. Br J Ophthalmol. 2019;103(1):1-2.
  22. Cimdins K, Waugh HS, Chrysostomou V, Lopez Sanchez MIG, Johanssen VA, Cook MJ, et al. Correction to: Amyloid Precursor Protein Mediates Neuronal Protection from Rotenone Toxicity. Mol Neurobiol. 2019;56(10):7249.